Vertex Pharmaceuticals Q2 Adj EPS $3.89 Beats $3.85 Estimate, Sales $2.49B Beat $2.41B Estimate
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals reported Q2 adjusted earnings of $3.89 per share, beating the analyst consensus estimate of $3.85 by 1.04%. This is an 8.06% increase from the same period last year. The company also reported quarterly sales of $2.49 billion, beating the analyst consensus estimate of $2.41 billion by 3.44%, a 13.52% increase from the same period last year.
August 04, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex Pharmaceuticals reported better than expected Q2 earnings and sales, indicating strong performance.
Vertex Pharmaceuticals reported Q2 earnings and sales that beat analyst estimates, indicating strong performance. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100